IN THE CLAIMS

1-21. (canceled)

22. (previously presented) A tablet comprising:

a) a pharmaceutically effective amount of fentanyl or its pharmaceutically acceptable salt for oral administration across the oral mucosa, including buccal, sublingual and gingival administration;

b) at least one pH adjusting substance which is a base and selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate; and

c) at least one saliva activated effervescent couple present in an amount which is greater than the amount necessary for tablet disintegration, said effervescent couple comprising an acid selected from the group consisting of citric, tartaric, malic, fumaric, adipic and succinic acid, and a base selected from sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, and magnesium carbonate;

wherein said amount of said at least one effervescent couple is between about 20% by weight and about 80% by weight;

d) up to about 20 weight percent of a non-effervescent disintegration agent; and

e) which (b) and (c) are sufficient to increase permeability of said fentanyl or its pharmaceutically acceptable salt across the oral mucosa;

said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

23. (canceled)

24. (canceled)

25. (previously presented) The tablet of claim 22, further comprising a bioadhesive, wherein said bioadhesive

increases the contact time between said tablet and the oral mucosa.

26. (canceled)

27. (previously presented) The tablet of claim 22, further comprising glidants, lubricants, binders, sweeteners, flavoring and coloring components.

28. (canceled)

29. (canceled)

30. (previously presented) A tablet comprising:

a) a pharmaceutically effective amount of fentanyl or its pharmaceutically acceptable salt for oral administration across the oral mucosa and capable of existing in an ionized form and an unionized form in the mouth;

b) at least one saliva activated effervescent couple present in an amount which is greater than the amount necessary for tablet disintegration, wherein said amount of said at least one effervescent couple is between about 20% by weight and about 80% by weight;

c) at least one pH adjusting substance which is a base, present in an amount which is sufficient to change the pH of a local environment of said dosage form at a site of absorption in the mouth to favor said unionized form of said medicament;

d) up to about 20 weight percent of a non-effervescent disintegration agent; and

e) which (b) and (c) are sufficient to increase permeability of said medicament across the oral mucosa;

said tablet suitable for administration of said medicament across the oral mucosa.

31. (previously presented) The tablet of claim 30, further comprising at least one glidant, lubricant, binder, sweetener, flavor or color.

32. (previously presented) The tablet of claim 30, further comprising a bioadhesive, wherein said bioadhesive

increases the contact time between said tablet and the oral mucosa.

33. (previously presented) The tablet as in any one of claims 22 and 30, wherein said non-effervescent disintegration agent is selected from the group consisting of microcrystalline cellulose, croscarmellose sodium, crospovidone, corn starch, potato starch, modified corn starch, modified potato starch, bentonite, alginates, agar, guar, locust bean, karaya, pectin and tragacanth.

34-82. (canceled)

83. (previously presented) The tablet of claim 22, wherein said at least one pH adjusting substance is present in an amount which is sufficient to change the pH of a local environment of said tablet at a site of absorption in the mouth to favor an unionized form of said medicament.

84-85. (canceled)

86. (previously presented) The tablet of claim 30, wherein said base is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate.

87. (canceled)

88. (previously presented) The tablet of claim 22 wherein said at least one pH adjusting substance is present in an amount which is sufficient to change the pH of a local environment of said medicament at a site of absorption in the mouth.

89. (canceled)

90. (canceled)

91. (previously presented) The tablet of claim 22 which is adapted for buccal administration.

92. (canceled)

93. (previously presented) The tablet of claim 22 which is adapted for gingival administration.

94. (previously presented) The tablet of claim 22 which is adapted for sublingual administration.

95-104. (canceled)

105. (previously presented) A tablet comprising:

a) a pharmaceutically effective amount of fentanyl citrate;

b) a pH adjusting substance comprising sodium carbonate; and

c) an effervescent couple present in an amount which is greater than the amount necessary for tablet disintegration, said effervescent couple comprising citric acid and sodium bicarbonate;

wherein said amount of said at least one effervescent couple is between about 20% by weight and about 80% by weight;

d) up to about 20 weight percent of a non-effervescent disintegration agent; and

e) which (b) and (c) are sufficient to increase permeability of said fentanyl citrate across the oral mucosa;

said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa;

wherein said tablet is formulated for oral administration of said fentanyl citrate across the oral mucosa.

106. (new) A tablet comprising:

a) a pharmaceutically effective amount of fentanyl citrate;

b) a pH adjusting substance which is a base and is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate;

c) at least one saliva activated effervescent agent present in an amount which is greater than the amount necessary for tablet disintegration and which is from about 30% to about

80% by weight of said tablet, said effervescent agent comprising an acid selected from the group consisting of citric, tartaric, malic, fumaric, adipic and succinic acid, and a base selected from sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, and magnesium carbonate; and

d) up to about 20 weight percent of a non-effervescent disintegration agent;

said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

107. (new) The tablet of claim 106, further comprising at least one glidant, lubricant, binder, sweetener, flavor or color.

108. (new) A tablet comprising:

a) a pharmaceutically effective amount of fentanyl citrate;

b) a pH adjusting substance which is a base and is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate;

c) at least one effervescent agent present in an amount which is greater than the amount necessary for tablet disintegration and which is from about 30% to about 80% by weight of said tablet; and

d) up to about 20 weight percent of a non-effervescent disintegration agent;

said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

109. (new) The tablet of claim 108 wherein said effervescent agent is selected from the group consisting of citric, tartaric, malic, fumaric, adipic, succinic acid, sodium

bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, and magnesium carbonate.

110. (new) The tablet of claim 108, further comprising at least one glidant, lubricant, binder, sweetener, flavor or color.